DAY ONE BIOPHARMACEUTICALS I (DAWN)       20.24  +0.18 (+0.9%)

20.24  +0.18 (+0.9%)

US23954D1090 - Common Stock

DAY ONE BIOPHARMACEUTICALS I20.24

NASDAQ:DAWN (10/4/2022, 12:29:01 PM)+0.18 (+0.9%)

Chartmill TA Rating
Chartmill Setup Rating
Sector
GICS Sector Health Care
GICS Industry Biotechnology
Chartmill FA Rating
Valuation Growth
Profitability Health
Dividend
Overview
Earnings (Last) 08-04 2022-08-04/amc Earnings (Next) N/A N/A
Ins Owners 39.02% Inst Owners 80.85%
Market Cap 1.49B Shares 73.46M
PE N/A Fwd PE N/A
Dividend Yield N/A Analysts 84
IPO 05-27 2021-05-27

Stock Screener Links

Screen Image

Nasdaq Stock Screener

Find more stocks on Nasdaq

Screen Image

USA Stock Screener

Find more stocks on the USA

Screen Image

GICS Sector Stock Screener

Find competitors from the same sector on the USA

Screen Image

GICS Industry Stock Screener

Find competitors from the same industry on the USA

Screen Image

Technical Stock Screener

Find stocks with similar TA and Setup ratings on the USA

Screen Image

Fundamental Stock Screener

Find stocks with similar Fundamental rating on the USA

Screen Image

Best Technical Competitors Stock Screener

Find the competitors with the best technical ratings on the USA

Screen Image

Best Technical Setups Competitors Stock Screener

Find the competitors with the best technical and setup ratings on the USA

Screen Image

Best Fundamental Competitors Stock Screener

Find the competitors with the best fundamentals on the USA

Screen Image

Best Valuation Competitors Stock Screener

Find the competitors with the best valuation on the USA

Screen Image

Best Dividend Competitors Stock Screener

Find the competitors with the best dividend on the USA

Screen Image

Best Analyst Rating Competitors Stock Screener

Find the competitors with the best analyst ratings on the USA

DAWN Daily chart

Company Profile

Day One Biopharmaceuticals, Inc. operates as a holding company. The company is headquartered in South San Francisco, California and currently employs 94 full-time employees. The company went IPO on 2021-05-27. The company is focused on developing and commercializing targeted therapies for patients of all ages with genomically-defined cancers. The company seeks to identify, acquires, and develops product candidates that target high-value oncogenic drivers in cancers with unmet need, with an initial focus on pediatric patients. Its lead product candidate, DAY101 (tovorafenib), is an oral, brain-penetrant, highly selective type II pan-rapidly accelerated fibrosarcoma (pan-RAF), kinase inhibitor. Tovorafenib is also used for the treatment of low-grade gliomas (LGGs). Its second product candidate, pimasertib, is an oral, highly selective small molecule inhibitor of mitogen-activated protein kinase kinases 1 and 2 (MEK), a key signaling node in the MAPK pathway. The company has initiated a phase II trial of tovorafenib for pediatric patients with relapsed or progressive low-grade glioma (pLGG), the common brain tumor diagnosed in children.

Company Info

DAY ONE BIOPHARMACEUTICALS I

395 Oyster Point Blvd Ste 217

South San Francisco CALIFORNIA

P: 12069134300.0

CEO: Jeremy Bender

Employees: 94

Website: https://dayonebio.com/

DAWN News

News Image13 days ago - Market News VideoDay One Biopharmaceuticals Enters Oversold Territory (DAWN)News Image22 days ago - Day One Biopharmaceuticals, Inc.Day One Appoints Garry Nicholson as Chairman of the Board of Directors

SOUTH SAN FRANCISCO, Calif., Sept. 12, 2022 (GLOBE NEWSWIRE) -- Day One Biopharmaceuticals (Nasdaq: DAWN), a clinical-stage biopharmaceutical company...

News Imagea month ago - Market News VideoFirst Week of DAWN April 2023 Options TradingNews Image2 months ago - Day One Biopharmaceuticals, Inc.Day One Reports Second Quarter 2022 Financial Results and Corporate Progress

Reported positive initial data from ongoing pivotal FIREFLY-1 study with tovorafenib (DAY101) in relapsed pediatric low-grade glioma (pLGG); topline...

News Image2 months ago - Day One Biopharmaceuticals, Inc.Day One to Participate in the 2022 Wedbush PacGrow Healthcare Virtual Conference

SOUTH SAN FRANCISCO, Calif., Aug. 02, 2022 (GLOBE NEWSWIRE) -- Day One Biopharmaceuticals (Nasdaq: DAWN), a clinical-stage biopharmaceutical company...

News Image2 months ago - Market News VideoNotable Friday Option Activity: ROKU, DAWN, PING

DAWN Twits

Here you can normally see the latest stock twits on DAWN, but your cookie settings prevent this from loading. You can edit your cookie settings in our cookie consent dialog.

Example Twits:

Twits example